Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | PPARG | P37231 | 1/20 | 0.53 |
| ▸ | PPARA | Q07869 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.43 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14532784 | 1.00 | LMNA (0.63) | LMNAPPARGPPARAATMMEN1 | |
| SCHEMBL6539801 | 1.00 | LMNA (0.63) | LMNAPPARGPPARAATMMEN1 | |
| SCHEMBL30454910 | 0.89 | PPARG (0.55) | LMNAPPARGPPARAATMMEN1 | |
| SCHEMBL13658641 | 0.89 | PPARG (0.53) | LMNAPPARGPPARAATMMEN1 | |
| SCHEMBL2789835 | 0.88 | PPARG (0.54) | LMNAPPARGPPARAATMMEN1 | |
| SCHEMBL2617240 | 0.88 | PPARG (0.54) | LMNAPPARGPPARAATMMEN1 | |
| SCHEMBL2789840 | 0.88 | PPARG (0.54) | LMNAPPARGPPARAATMMEN1 | |
| SCHEMBL2617242 | 0.87 | PPARG (0.51) | LMNAPPARGPPARAATMMEN1 | |
| SCHEMBL3222299 | 0.86 | MAPT (0.52) | LMNAPPARGPPARAATMITGA4 | |
| SCHEMBL3222312 | 0.86 | MAPT (0.52) | LMNAPPARGPPARAATMITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250127939-A1 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | PURDUE RESEARCH FOUNDATION | 2025-04-24 | — | — | US | disclosed |
| EP-4541378-A2 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | Endocyte, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| EP-3777898-B1 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | ENDOCYTE INC (US) | 2025-01-01 | — | — | EP | disclosed |
| US-12178892-B2 | Compounds for positron emission tomography | PURDUE RESEARCH FOUNDATION (US) | 2024-12-31 | — | — | US | disclosed |
| US-20220125958-A1 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | PURDUE RESEARCH FOUNDATION | 2022-04-28 | — | — | US | disclosed |
| EP-3472130-B1 | ALIPHATIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3777898-A2 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | Endocyte, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3533473-A2 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | Endocyte, Inc. (US) | 2019-09-04 | — | — | EP | disclosed |
| US-9988420-B2 | Cytotoxic peptides and conjugates thereof | NOVARTIS AG (CH) | 2018-06-05 | — | — | US | disclosed |
| US-20170008863-A1 | SYNTHESIS OF THERAPEUTIC AND DIAGNOSTIC DRUGS CENTERED ON REGIOSELECTIVE AND STEREOSELECTIVE RING OPENING OF AZIRIDINIUM IONS | CHONG, HYUN-SOON, PHD | 2017-01-12 | — | — | US | disclosed |
| WO-2015073678-A1 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | ENDOCYTE, INC. (US) | 2015-05-21 | — | — | WO | disclosed |
| US-20100322855-A1 | Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using | ILLINOIS INSTITUTE OF TECHNOLOGY (US) | 2010-12-23 | — | — | US | disclosed |
| EP-0873308-B1 | O-CARBAMOYL-PHENYLALANINOL COMPOUNDS AND THEIR PHARMACEUTICALLY USEFUL SALTS | SK CORP (KR) | 2002-01-02 | — | — | EP | disclosed |
| EP-0820438-B1 | O-CARBAMOYL-PHENYLALANINOL HAVING SUBSTITUENT AT BENZENE RING, ITS PHARMACEUTICALLY USEFUL SALTS AND METHOD FOR PREPARING THE SAME | SK CORP (KR) | 2001-06-20 | — | — | EP | disclosed |
| US-6140532-A | O-carbamoyl-phenylalaninol having substituent at benzene ring, its pharmaceutically useful salts and method for preparing the same | SK CORPORATION (US) | 2000-10-31 | — | — | US | disclosed |
| EP-0873308-A1 | O-CARBAMOYL-PHENYLALANINOL COMPOUNDS, THEIR PHARMACEUTICALLY USEFUL SALTS AND PROCESS FOR PREPARING THE SAME | SK Corporation (KR) | 1998-10-28 | — | — | EP | disclosed |
| US-5756817-A | TREATMENT OF DISEASES OF CENTRAL NERVOUS SYSTEMS | YUKONG LIMITED (KR) | 1998-05-26 | — | — | US | disclosed |
| WO-1998015526-A1 | O-CARBAMOYL-PHENYLALANINOL COMPOUNDS, THEIR PHARMACEUTICALLY USEFUL SALTS AND PROCESS FOR PREPARING THE SAME | SK CORPORATION (KR) | 1998-04-16 | — | — | WO | disclosed |
| EP-0820438-A1 | O-CARBAMOYL-PHENYLALANINOL HAVING SUBSTITUENT AT BENZENE RING, ITS PHARMACEUTICALLY USEFUL SALTS AND METHOD FOR PREPARING THE SAME | YUKONG LIMITED (KR) | 1998-01-28 | — | — | EP | disclosed |
| WO-1996032375-A1 | O-CARBAMOYL-PHENYLALANINOL HAVING SUBSTITUENT AT BENZENE RING, ITS PHARMACEUTICALLY USEFUL SALTS AND METHOD FOR PREPARING THE SAME | YUKONG LIMITED (KR) | 1996-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250127939-A1 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | VHL, PC, NPC1 | LMNA 2072/4885PPARG 405/4885PPARA 1416/4885 |
| US-12178892-B2 | Compounds for positron emission tomography | FOLH1, FOLR2, FOLR1 | LMNA 1873/4885PPARG 1771/4885PPARA 1516/4885 |
| US-20170008863-A1 | SYNTHESIS OF THERAPEUTIC AND DIAGNOSTIC DRUGS CENTERED ON REGIOSELECTIVE AND STEREOSELECTIVE RING OPENING OF AZIRIDINIUM IONS | AZI2, ABL1, DHPS | LMNA 4686/4885PPARG 4673/4885PPARA 4775/4885 |
| US-20100322855-A1 | Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using | UACA, CLTC, PKD1 | LMNA 559/4885PPARG 1225/4885PPARA 873/4885 |
| US-20220125958-A1 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | FOLH1, FOLR2, FOLR1 | LMNA 1873/4885PPARG 1771/4885PPARA 1516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.